MIRFARM
shaping the future of medicine
A full‑cycle international group of companies
MIRFARM
shaping the future of medicine
shaping the future of medicine
A full‑cycle international group of companies
Our Mission
Making therapy accessible
We believe access to modern treatment is a right for everyone. Our primary focus is medicines for orphan (rare) diseases. In close collaboration with leading experts and the medical community, we develop and bring to the Russian market medicines that give patients hope and improve quality of life.
MIRPHARM Today
- 26 yearsof uninterrupted growth
- 20+ tonsof pharmaceutical substances (APIs) per year
- 8+ millionpacks of medicines per year
- 100+medicines in the development and registration pipeline
Our Values
- Responsibility and TransparencyWe conduct business with integrity, building long‑term, trusted relationships with partners, the medical community, and patients. Our foremost responsibility is people’s health.
- Scientific ExcellenceContinuous capability development, investment in research, and the deployment of advanced technologies are the foundation of our leadership and product quality. We operate at the leading edge of pharmaceutical science.
- Earning Trust Through ResultsWe value the trust of physicians and partners, reinforcing it every day through the efficacy of our medicines, reliable supply, and dependability across all aspects of collaboration.
From idea to registration. Our R&D centers in Russia and the EU specialize in developing synthesis technologies for pharmaceutical substances of any complexity and in creating finished dosage forms, in line with modern requirements for efficacy and safety.
R&D: Research and Development
State‑of‑the‑art production sites certified to GMP standards. We maintain full control at every stage—from substance synthesis to release and packaging of finished medicines—ensuring uncompromising product quality.
High‑Tech Manufacturing Facilities
Our Capabilities
Our History
1999
The company—the nucleus of the future MIRPHARM Group—was founded. Foundations for in‑house high‑tech manufacturing were laid and a clear development trajectory was set. This marked a significant milestone for the Russian pharmaceutical industry.
2001
In Russia’s first “science city,” Obninsk, we launched our own manufacturing site—the Obninsk Chemical and Pharmaceutical Company (OCPC). Established on the basis of the Medical Radiological Research Center of the Russian Academy of Medical Sciences, it became the first chemical‑pharmaceutical production facility in Kaluga Region. Responding to market needs, the site focused on producing active pharmaceutical ingredients (APIs).
2002
The first substance introduced into industrial production was Diazolin, enabling domestic manufacturers to replace imports with high‑quality local raw materials.
2003
A solid‑dosage manufacturing workshop was opened, and a large‑scale plant modernization brought the facility into full compliance with Good Manufacturing Practice (GMP). The workshop was equipped with advanced IMA (Italy) and GLATT (Germany) lines, as well as high‑precision quality control laboratory equipment.
2008
We expanded our portfolio with new substances and launched the medicine Tranexam®. A long‑term partnership was established with STADA (JSC “Nizhpharm”).
2011-2013
We opened our own research and production sites in the European Union, established technology exchange, and gained access to leading international expertise and global markets.
2012
The OCPC site became one of the first in Russia to pass an international inspection and receive a GMP certificate, opening the door to exports. The company ranked among the Top‑30 laureates of the national TechUp rating, a strong recognition of our technological competence.
2017
We began developing medicines for rare (orphan) diseases. In 2018, the antineoplastic medicine Mitotane for the treatment of adrenocortical carcinoma was registered—opening a new chapter for the company and improving access to high‑tech therapies for patients.
2020-2024
We developed and launched more than ten modern medicines across multiple therapeutic areas. Four of them—diazoxide (Diazoxide MIRPHARM), flecainide (Fleikardil®), avatrombopag (Troplastim®), and bempedoic acid (Lipless®)—became available to patients in Russia and the EAEU for the first time.
2024-2025
Construction and launch of a new high‑tech manufacturing complex in Obninsk. The plant obtained a manufacturing license and an EAEU GMP certificate, confirming compliance with the strictest quality standards. The complex integrates warehousing, process lines, and laboratories, ensuring a full end‑to‑end medicines lifecycle.
Continuing Momentum Today, we are not slowing down. Every year, dozens of new medicines enter development. Many become the first generics on the market, opening access to therapies that were previously unavailable to Russian patients. We are steadily expanding our portfolio and strengthening our market position, guided by our core purpose—caring for people’s health.
We use technical and analytical cookies to improve your experience.